In the recent history of psychedelic policy, no single date was greeted with as much optimism as July 1, 2023. On that day Australia became the first country in the world to recognize MDMA and psilocybin as medicines. The coverage was euphoric and the media called it a watershed. For a movement accustomed to losing, it looked like the levee had finally broken.
Three years on, the number of Australians who have received the treatment is less than two hundred. This was roughly during the same period when over 20,000 psilocybin sessions were held in Oregon. What the hell happened in Australia?
The failure of the rollout in Australia did not happen through any reversal of policy. What defeated it were the requirements. As someone who has spent a working career in federal health regulations, it is not the first time I’ve seen sensible rules strangle the things they were written to permit.
Let’s start with what Australia did, because nearly every headline got it wrong. Australia did not approve MDMA or psilocybin. MDMA and psilocybin are not on the Australian Register of Therapeutic Goods. What the government did was cut a narrow door into an existing mechanism called the Authorized Prescriber process. This was a pathway ordinarily used to get an unregistered drug to a defined patient population under a named doctor’s supervision. It was a regulatory workaround presented to the public as a reform. The door it opened has four locks on it, and together they made significant access unlikely.
The first lock is the prescriber, and only a psychiatrist may prescribe MDMA or psilocybin. Psychiatry in Australia was already a specialty in shortage and their national association itself had opposed the rescheduling.
Then ethics approval. The psychiatrist must write a complete treatment protocol, covering dosing, screening, monitoring, adverse event handling, and risk mitigation, and submit it to a Human Research Ethics Committee registered with the National Health and Medical Research Council. Committees meet on their own calendars and send protocols back for revision. There is no approved template to copy and every psychiatrist writes one from scratch and defends it.
The authorization itself comes only after ethics clearance, and it is granted separately for each indication. MDMA for PTSD is one authorization. Psilocybin for treatment-resistant depression is another.
Supply is the fourth lock. With nothing on the Register, clinics import pharmaceutical grade MDMA and psilocybin. This entails Office of Drug Control permits, import exemptions, and a supply chain resting on a handful of overseas manufacturers. On top of all this sits a standing obligation to report patient numbers and adverse events every six months for as long as you prescribe.
The result is what you would expect. By August 2025 in a country of twenty-seven million there were only twelve psychiatrists listed on the public directory of authorized prescribers. By the end of that year additional authorizations had been granted but literally a handful of prescribers are holding the keys to access.
Now consider the other side of the door. To receive MDMA legally in Australia you must have post-traumatic stress disorder. To receive psilocybin, you must have treatment-resistant depression, meaning you have already failed adequate trials of conventional treatment, though there was never fixed a national threshold for what counts as adequate. That definition lives inside each psychiatrist’s ethics-approved protocol, which means it varies from clinic to clinic. Nothing else qualifies — not end-of-life anxiety, where the psilocybin evidence is arguably strongest, and not alcohol use disorder, obsessive-compulsive disorder, anorexia, or cluster headaches.
You must then find and be accepted by one of those approved psychiatrists, most of whom practice in Sydney, Melbourne, or Brisbane. You must pass medical and psychiatric screening, and a personal or family history of psychosis or bipolar disorder will usually disqualify you, as well as a range of cardiac conditions. What you are signing up for is a course of care. Preparation sessions first, then one or more dosing days that run six to eight hours under continuous supervision, then integration sessions afterward.
And you must pay for all of it out of your own pocket. Because the substances are unapproved goods they cannot be listed on the Pharmaceutical Benefits Scheme, so there is no subsidy. A peer-reviewed analysis published this year put real-world psilocybin protocols at upwards of fifteen thousand USD dollars per patient. The cost of a MDMA protocol is even higher. The drug itself is cheap. What costs money is clinician hours: two trained practitioners sitting in a room for eight hours at a stretch, three or four times over.
Here is the detail that makes Australia worth studying. The treatment worked. Across the entire program, no serious adverse events have been reported. The safety case that all those requirements were built to protect has been made, and it was made partly by demonstrating that the requirements were not necessary at the scale they permitted.
In June 2026 eighty-three stakeholders proposed loosening the rules on treatment teams. Instead of a psychiatrist remaining in the room for the entire session, the requirement would become a minimum of one health practitioner, with psychotherapists, counsellors, and social workers eligible to occupy the second chair. The Royal Australian and New Zealand College of Psychiatrists responded that this posed an unjustifiable risk to patient safety.
The sequence is worth laying out. The College that opposed the original rescheduling, whose members are the only people legally permitted to prescribe, and whose billable hours constitute the largest single line item in a fifteen-thousand-dollar course of treatment, is now opposing the one change that would make that treatment affordable, on safety grounds, in a program that has recorded no serious adverse events in three years. I am not suggesting bad faith. I have sat in enough regulatory rooms to know that the people making these arguments usually believe every word. That is precisely the difficulty. Gatekeeping does not require anyone to be dishonest. It only requires that the people writing the rules be drawn from the same profession the rules protect, and that no one is assigned to count the patients who never got through the door.
Americans should watch this closely, because we are busy assembling our own version of the same machine. Australia is the clarifying case, because Australia obtained the very thing every advocate here says they want. Full national legal recognition, medicine status, a government blessing, and headlines around the world. Even with all that less than two hundred people in Australia have gained above ground access to treatment.
The lesson I take from this is that legalization is not access, and that the two get confused constantly by people who should know better. A law permitting a treatment that nobody can reach is a press release, not a policy, and the honest question to ask of any new framework is how many people finished treatment last year. Whoever controls the bottleneck sets the price, so restricting delivery to the scarcest and most expensive professional class in medicine guarantees a fifteen-thousand-dollar treatment and a boutique clientele.
That is the lesson in Australia’s rollout of psychedelic assisted therapy. The headlines were real enough; the access never arrived, and until it does the rest is decoration.
Excellent read! Thank you.